Novocure Ltd (NVCR)

[Galzus Research]

Insults really do add to your credibility.

Professionals stopped publishing responses related to DCVax as soon as they stopped publishing meaningful studies that had the chance to change the standard of care. Contrary to what you may think, the vast majority of oncologists, even those in the neuro-oncology space, aren't thinking about dendritic cell vaccination as a particularly attractive way forward.

In short, the critics stopped publicly commenting on it because it stopped being a topic of conversation within a few months of being published. Just like most studies that don't lead to an FDA submission. Note that no one has commented, positively or negatively, on the pilot trial with poly-ICLC.

So instead of sputtering uselessly about your opinion on my research skills, you could do some work to refute things I've said. Then I would respond to you again. As for now, that's all you'll get from me. Listen or don't.